Fresenius SE KGaA's revenue per share for the
three
months ended in Mar. 2026 was CHF9.40.
Fresenius SE KGaA's revenue per share for the trailing twelve months (TTM) ended in Mar. 2026 was CHF38.04.
Warning Sign:
Fresenius SE & Co KGaA revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue Per Share Growth Rate of Fresenius SE KGaA was 3.40% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was 1.90% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was -10.80% per year.
During the past 10 years, the average Revenue Per Share Growth Rate was -4.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Fresenius SE KGaA's Revenue per Share or its related term are showing as below:
XSWX:FRE'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -26 Med: 4.8 Max: 12.5
Current: 1.9
During the past 13 years, Fresenius SE KGaA's highest 3-Year average Revenue Per Share Growth Rate was 12.50% per year. The lowest was -26.00% per year. And the median was 4.80% per year.
XSWX:FRE's 3-Year Revenue Growth Rate is ranked worse than 66.72% of 613
companies
in the Healthcare Providers & Services industry
Industry Median: 6.9
vs XSWX:FRE: 1.90
Fresenius SE KGaA (XSWX:FRE) Revenue per Share Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Fresenius SE KGaA Revenue per Share Related Terms
Fresenius SE KGaA Revenue per Share Historical Data
* Premium members only.
The historical data trend for Fresenius SE KGaA's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:FRE vs HCA, THC, DVA: Revenue per Share Comparison
For the Medical Care Facilities subindustry, Fresenius SE KGaA's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fresenius SE KGaA PS Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Fresenius SE KGaA's PS Ratio distribution charts can be found below:
* The bar in red indicates where Fresenius SE KGaA's PS Ratio falls into.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Fresenius SE KGaA's Revenue Per Share for the fiscal year that ended in Dec. 2025 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF38.04
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fresenius SE KGaA (XSWX:FRE) has a Revenue per Share of CHF38.04 as of Mar. 2026. Revenue per share equals the per-share value of a company's sales. View historical data on Fresenius SE KGaA and its competitors. According to the industry distribution chart, Fresenius SE KGaA ranks #409 out of 613 companies in the Healthcare Providers & Services industry, placing it in the top 66.7%.
Is Fresenius SE KGaA's Revenue per Share too high?
Fresenius SE KGaA's current Revenue per Share is CHF38.04. Based on the distribution chart, Fresenius SE KGaA ranks #409 out of 613 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Fresenius SE KGaA has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does Fresenius SE KGaA's Revenue per Share compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Fresenius SE KGaA ranks #409 out of 613 companies for Revenue per Share. This places Fresenius SE KGaA in the lower half of its industry. The industry median Revenue per Share is 6.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Healthcare Providers & Services company?
The median Revenue per Share among Healthcare Providers & Services companies is 6.90, based on 613 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Fresenius SE KGaA and its competitors. For the Healthcare Providers & Services industry, the median Revenue per Share is 6.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fresenius SE KGaA's current Revenue per Share is CHF38.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fresenius SE KGaA stock overvalued right now?
Fresenius SE KGaA (XSWX:FRE) has a current Revenue per Share of CHF38.04. The stock's GF Value™ is CHF33.76, compared to a current price of CHF39.27 — trading 16.3% above its estimated fair value. The current Revenue per Share is CHF38.04. Fresenius SE KGaA's overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Fresenius SE KGaA (XSWX:FRE), the current Revenue per Share is CHF38.04 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fresenius SE KGaA (XSWX:FRE) Overvalued in 2026?
Based on GuruFocus' analysis, Fresenius SE KGaA stock appears to be overvalued.
The current stock price of CHF39.27 is trading 16.3% above its estimated GF Value™ of CHF33.76.
Key valuation signals for XSWX:FRE:
Revenue per Share: CHF38.04
GF Value™: CHF33.76 vs. price of CHF39.27 (16.3% above fair value)
No single metric tells the full story. See the XSWX:FRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fresenius is a healthcare holding company based in Germany. The company owns a minority stake in dialysis service provider and equipment manufacturer Fresenius Medical Care. The Kabi segment manufactures intravenous drugs, nutrition products, infusion and transfusion therapies, and related pumps. The Helios segment operates private hospitals primarily in Germany and Spain.
69GF Score
Get the complete analysis for XSWX:FRE
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:FRE has been successfully added to your 
